Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mona Arab-Alameddine, Laurent Arhtur Décosterd, Thierry Buclin, Amalio Telenti & Chantal Csajka. (2011) Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 609-622.
Read now
Read now
Lisa M Chirch & Roy T Steigbigel. (2010) Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection. Infection and Drug Resistance 3, pages 15-23.
Read now
Read now
Articles from other publishers (12)
Isis Regina Grenier Capoci, Daniella Renata Faria, Karina Mayumi Sakita, Franciele Abigail Vilugron Rodrigues-Vendramini, Patricia de Souza Bonfim-Mendonça, Tania Cristina Alexandrino Becker, Érika Seki Kioshima, Terezinha Inez Estivalet Svidzinski & Bernard Maigret. (2019) Repurposing approach identifies new treatment options for invasive fungal disease. Bioorganic Chemistry 84, pages 87-97.
Crossref
Crossref
Umesh Kalathiya, Monikaben Padariya & Maciej Baginski. (2018) Extracting functional groups of ALLINI to design derivatives of FDA-approved drugs: Inhibition of HIV-1 integrase. Biotechnology and Applied Biochemistry 65:4, pages 594-607.
Crossref
Crossref
M. Tozammel Hoque, Olena Kis, María F. De Rosa & Reina Bendayan. (2015) Raltegravir Permeability across Blood-Tissue Barriers and the Potential Role of Drug Efflux Transporters. Antimicrobial Agents and Chemotherapy 59:5, pages 2572-2582.
Crossref
Crossref
Said A. Hassounah, Thibault Mesplède, Peter K. Quashie, Maureen Oliveira, Paul A. Sandstrom & Mark A. Wainberg. (2014) Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors. Journal of Virology 88:17, pages 9683-9692.
Crossref
Crossref
Nouri Neamati. 2011. HIV‐1 Integrase. HIV‐1 Integrase
165
196
.
Darren M. Moss, Wai San Kwan, Neill J. Liptrott, Darren L. Smith, Marco Siccardi, Saye H. Khoo, David J. Back & Andrew Owen. (2011) Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy 55:2, pages 879-887.
Crossref
Crossref
Mark G Lewis, Sandro Norelli, Matt Collins, Maria Letizia Barreca, Nunzio Iraci, Barbara Chirullo, Jake Yalley-Ogunro, Jack Greenhouse, Fausto Titti, Enrico Garaci & Andrea Savarino. (2010) Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7:1.
Crossref
Crossref
Jean-François Mouscadet & Didier Desmaële. (2010) Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors. Molecules 15:5, pages 3048-3078.
Crossref
Crossref
Jerome Wielens, Stephen J. Headey, Dharshini Jeevarajah, David I. Rhodes, John Deadman, David K. Chalmers, Martin J. Scanlon & Michael W. Parker. (2010) Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site. FEBS Letters 584:8, pages 1455-1462.
Crossref
Crossref
John F. Miller, Elizabeth M. Turner, Kristjan S. Gudmundsson, Stephen Jenkinson, Andrew Spaltenstein, Michael Thomson & Pat Wheelan. (2010) Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorganic & Medicinal Chemistry Letters 20:7, pages 2125-2128.
Crossref
Crossref
Jocelyn S DowneyNesrina Imami. (2010) T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Therapy 4:1, pages 83-99.
Crossref
Crossref
Jean-François Mouscadet & Luba Tchertanov. (2009) Raltegravir: molecular basis of its mechanism of action. European Journal of Medical Research 14:Suppl 3, pages 5.
Crossref
Crossref